Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Aug 4;11:15791. doi: 10.1038/s41598-021-95305-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

PAM-AMA analysis in n = 4942 individuals from the population based MPP study cohort. (A) Frequency distribution of PAM-AMA. The data did not pass the D’Angostino–Pearson omnibus test for normal distribution; a normal distribution curve (solid line) was fitted into the frequency distribution of the cohort. The 95% CI is shown as dotted lines. Kaplan Meier analysis for all-cause mortality risk (B), cardiovascular mortality risk (C), heart failure risk (D) and atrial fibrillation risk (E) in relation to serum AMA levels. Subjects analyzed in (C) and (D) were free of heart failure or atrial fibrillation at baseline. Over the follow-up time of 12.8 years the cumulative rates of each indication differed between the highest quartile of AMA (Q4) and the lowest Quartile of AMA (Q1). Quantitative analyses are summarized in Table 4 (B,C) and Table 5 (D,E). PAM-AMA in subjects from the MPP-cohort was categorized according to systolic- (F,G) and diastolic blood pressure (H,I). The population was divided in subject not receiving antihypertensive treatment (F,H) and in subjects receiving antihypertensive treatment (G,I). Difference in PAM-AMA was analyzed via one-way ANOVA (Dunn’s correction). Significance of differences is shown in each panel, n.s. not significant.